Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. TVTX
TVTX logo

TVTX News & Events

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

TVTX News

Analysis of XBI ETF Trading Dynamics

Jun 24 2026NASDAQ.COM

Travere Therapeutics Upgraded to Buy Rating

Jun 22 2026Yahoo Finance

Leadership Transition at Travere Therapeutics

Jun 16 2026Newsfilter

Travere Therapeutics Grants Equity Inducements to New Employees

Jun 11 2026Newsfilter

Long-term Results of FILSPARI Show Significant Efficacy

Jun 04 2026Newsfilter

Travere Licenses Civorebrutinib from Everest Medicines, Potential Best-in-Class Treatment

Jun 02 2026stocktwits

Travere Therapeutics and Everest Medicines Sign $1.1B Licensing Agreement

Jun 02 2026seekingalpha

Travere Therapeutics Grants Equity Inducements to New Employees

May 12 2026Newsfilter

TVTX Events

06/16 17:00
Travere Therapeutics Chief Research Officer Plans to Retire in February 2027
Travere Therapeutics "announced that William Rote, Ph.D., the Company's chief research officer, plans to retire from the Company in February 2027 following 10 years of service. Jula Inrig, M.D., currently chief medical officer and a member of the Company's executive leadership team, will expand her responsibilities to include the Company's research organization and be named executive vice president, head of research and development and CMO."

TVTX Monitor News

Travere Therapeutics Upgraded to Buy Rating

Jun 24 2026

Travere Therapeutics Grants RSUs to New Employees

Jun 15 2026

Travere Therapeutics grants RSUs to new employees to enhance retention

Jun 12 2026

Travere Therapeutics increases convertible notes offering to $475 million

May 07 2026

Travere Therapeutics reaches 52-week high amid market gains

May 05 2026

Travere Therapeutics stock rises amid market gains

Apr 30 2026

Travere Therapeutics' FILSPARI Receives FDA Approval for FSGS Treatment

Apr 14 2026

Travere Therapeutics Grants RSUs to New Employees

Feb 13 2026

TVTX Earnings Analysis

No Data

No Data

People Also Watch